This site is intended for healthcare professionals only.
Log in
Menu

Next-generation CAR-T cell therapy platforms for high-risk LBCL and R/R DLBCL: A round-up of 2025 breakthroughs

  • Experts in conversation
  • February 27, 2026

Leading experts Marco Davila, Gloria Iacoboni, Sairah Ahmed and Anna Sureda discuss and interpret the year’s most significant breakthroughs in next generation CAR-T cell therapy for high risk LBCL and R/R DLBCL, drawing on landmark data from EHA 2025 and ASH 2025.

Log in to access
No account? Register here for free

Faculty

marco-davila-headshot-276px

Marco Davila

Roswell Park Comprehensive Cancer Center, USA
gloria-iacoboni-headshot-800px

Gloria Iacoboni

Vall D'hebron University Hospital, Spain
sairah-ahmed-headshot-552px

Sairah Ahmed

The University of Texas MD Anderson Cancer Center, USA
ana-sureda-headshot-800px

Anna Sureda

Institut Català d'Oncologia - Hospital Duran i Reynals, Spain
Log in

Like this content?

Share with a colleague

Register for alerts

Complete the short registration form to be contacted when new learning content is made available, including ASH conference coverage, an “experts in conversation” webcast and free downloadable practice aid.

Log in to sign up for alerts